Please answer the following questions by circling the best response, or by filling in the blank.

**Demographics**

Age: ____________

Gender:  
  a. Male  
  b. Female

Race:  
  a. White  
  b. Black or African American  
  c. Asian  
  d. American Indian/Alaskan Native  
  e. Pacific Islander/Native Hawaiian  
  f. Other (specify) _______________

Ethnicity:  
  a. Hispanic or Latino  
  b. Not Hispanic or Latino

Profession:  
  a. Physician  
  b. Physician’s Assistant  
  c. Nurse/Advanced Nurse Practitioner  
  d. Phlebotomist  
  e. Other (specify) _______________

**Current TPMT Genotyping Procedures**

1. Is TPMT genotyping to guide dosing of thiopurine medications (i.e., mercaptopurine and thioguanine) currently part of your routine clinical care?  
   a. Yes  
   b. No  
   c. Does not apply

2. If yes, who is primarily responsible for returning TPMT genetic test results to patients?  
   a. Physician  
   b. Physician Assistant  
   c. Nurse/advanced nurse practitioner  
   d. Genetic counselor  
   e. Other (specify) ________________
3. Is TPMT phenotyping (enzyme assay) currently a part of your routine clinical care?  
   a. Yes  
   b. No  
   c. Does not apply

4. Is thiopurine metabolite monitoring currently a part of your routine clinical care?  
   a. Yes  
   b. No  
   c. Does not apply

5. How often do you use TPMT genotype results to determine the initial dose for the thiopurines?  
   a. Always  
   b. Nearly always  
   c. Sometimes  
   d. Rarely  
   e. Never  
   f. N/A

6. Have there been instances when thiopurine treatment has been postponed because TPMT genotype results were not available?  
   a. Yes  
   b. No  
   c. Does not apply

7. Have there been instances when thiopurine treatment has been postponed because TPMT genotype results were not easily accessible?  
   a. Yes  
   b. No  
   c. Does not apply

8. Are you able to find TPMT genotype results easily within the electronic medical record?  
   a. Always  
   b. Nearly always  
   c. Sometimes  
   d. Rarely  
   e. Never  
   f. N/A

9. Are you able to find TPMT genotype results consistently within the electronic medical record?  
   a. Always  
   b. Nearly always  
   c. Sometimes  
   d. Rarely  
   e. Never  
   f. N/A
10. Are the TPMT genotype results presented in a user-friendly manner within the electronic medical record?
   a. Always
   b. Nearly always
   c. Sometimes
   d. Rarely
   e. Never
   f. N/A

11. Do you currently receive the TPMT genotype results in a timely manner?
   a. Always
   b. Nearly always
   c. Sometimes
   d. Rarely
   e. Never
   f. N/A

12. What is your estimate of the average turnaround time (in business days) for the TPMT genotype results?
    a. 1-3 days
    b. 4-6 days
    c. 7-9 days
    d. >9 days
    e. I do not know

13. I am satisfied with the current process for ordering TPMT genotype testing.
    a. Strongly agree
    b. Agree
    c. Neutral
    d. Disagree
    e. Strongly disagree
    f. N/A

14. Our current process for returning TPMT genetic test results to patients are appropriate to meet patients’ needs.
    a. Strongly agree
    b. Agree
    c. Neutral
    d. Disagree
    e. Strongly disagree
    f. N/A
15. I can accurately apply the results of the TPMT genotype test to: (circle all that apply)
   a. Drug therapy dosing
   b. Drug therapy monitoring
   c. I cannot accurately apply the results of the TPMT genotype test
   d. Other (specify): __________________

16. I understand the role that TPMT genotype testing plays in adjusting the dose of thiopurines clinically.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

Updated TPMT Genotyping Procedures

17. I understand the rationale behind new procedures for TPMT genotyping within UF Health.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

18. I feel that the new procedures for TPMT genotype test ordering will be beneficial to patient care.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A
19. I feel that the new procedures for TPMT genotype test result documentation in the medical record will be beneficial to patient care.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

20. Clinical decision support in the electronic medical record (i.e., Epic alert) is an effective strategy to support TPMT genotype test ordering.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

21. Clinical decision support in the electronic medical record (i.e., Epic alert) is an effective strategy to support thiopurine dose adjustment based on TPMT genotype test results.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

22. I know who to contact if I have questions about the new TPMT genotype test ordering procedures.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A
General Pharmacogenomics

23. I believe that using genetics to guide therapeutic choices improves my ability to reduce adverse drug events.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

24. I believe that using genetics to guide therapeutic choices improves my ability to choose an effective treatment strategy for patients.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

25. I believe that pharmacogenetics is relevant to my current clinical practice.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

26. I am able to identify reliable sources of pharmacogenetic information in patient care.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A
27. I am able to *use* reliable sources of pharmacogenetic information *in patient care*.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

28. I am able to *identify* reliable sources of pharmacogenetic information *for patient education*.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

29. I am able to *use* reliable sources of pharmacogenetic information *for patient education*.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A

30. The UF Health Personalized Medicine Program enhances my ability to care for patients.
   a. Strongly agree
   b. Agree
   c. Neutral
   d. Disagree
   e. Strongly disagree
   f. N/A